$2.16
0.02% today
Nasdaq, Feb 28, 05:13 pm CET
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Innate Pharma - ADR Stock price

$2.16
+0.36 20.00% 1M
+0.00 0.00% 6M
+0.32 17.39% YTD
-0.53 19.62% 1Y
-1.25 36.66% 3Y
-5.78 72.80% 5Y
-3.89 64.30% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.10 4.42%
ISIN
US45781K2042
Symbol
IPHA
Sector
Industry

Key metrics

Market capitalization $181.03m
Enterprise Value $120.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.49
P/S ratio (TTM) P/S ratio 6.74
P/B ratio (TTM) P/B ratio 5.67
Revenue growth (TTM) Revenue growth -42.35%
Revenue (TTM) Revenue $26.87m
EBIT (operating result TTM) EBIT $-51.38m
Free Cash Flow (TTM) Free Cash Flow $-19.90m
EPS (TTM) EPS $-0.46
P/E forward negative
P/S forward 4.34
EV/Sales forward 2.89
Short interest 0.31%
Show more

Is Innate Pharma - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Innate Pharma - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Innate Pharma - ADR forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Innate Pharma - ADR forecast:

Buy
80%
Hold
20%

Financial data from Innate Pharma - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
27 27
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
29% 29%
60%
- Research and Development Expense 56 56
0% 0%
210%
-49 -49
70% 70%
-181%
- Depreciation and Amortization 2.80 2.80
56% 56%
10%
EBIT (Operating Income) EBIT -51 -51
47% 47%
-191%
Net Profit -37 -37
42% 42%
-137%

In millions USD.

Don't miss a Thing! We will send you all news about Innate Pharma - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innate Pharma - ADR Stock News

Neutral
Business Wire
one day ago
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.
Positive
Seeking Alpha
8 days ago
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a coll...
Neutral
Business Wire
11 days ago
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.
More Innate Pharma - ADR News

Company Profile

Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.

Head office France
CEO Jonathan Dickinson
Employees 179
Founded 1999
Website www.innate-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today